4.7 Article

Current Controversies and Future Perspectives in Chronic Obstructive Pulmonary Disease

出版社

AMER THORACIC SOC
DOI: 10.1164/rccm.201103-0405PP

关键词

diagnosis; epidemiology; inflammation; spirometry; systems biology

资金

  1. GlaxoSmithKline (GSK)
  2. Almirall
  3. Boehringer Ingelheim (BI)
  4. AstraZeneca (AZ)
  5. Esteve
  6. Novartis
  7. Nycomed
  8. Roche
  9. Chiesi Pharmaceuticals
  10. Pfizer

向作者/读者索取更多资源

Over the past decade there has been much research and interest in COPD. As a result, the understanding and management of the disease has improved significantly. Yet, there are many uncertainties and controversies that require further work. This review discusses these controversies and anticipates some of the changes that may occur in the near future in the field of COPD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据